Combining IMRT and lobaplatin chemo for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether combining a newer chemotherapy drug (lobaplatin) with standard radiation and chemotherapy is safe and effective for adults aged 65 to 80 with a certain type of nasopharyngeal cancer that hasn't spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma, confirmed by a biopsy.
- Your cancer is stage II, III, or IVa according to the UICC 8th edition staging system.
- You are between the ages of 65 and 80.
- Your liver, kidney, and blood cell counts are within a healthy range for your age.
- You are able to walk and care for yourself (a performance status of 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy drugs for people with nasopharyngeal cancer that has spread or come back. The goal is to see if it can help control the cancer and improve survival.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests combining induction chemotherapy and immunotherapy with radiation, with or without additional chemotherapy, for patients with advanced nasopharyngeal cancer (throat cancer). It aims to see if adding chemotherapy during radiation improves outcomes compared to not having it.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation can help people whose nasopharyngeal cancer has spread to the lungs or chest area. The treatment aims to shrink tumors and may improve outcomes for patients in this situation.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
Hear when a new Elderly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.